Positive Phase 3 Results in Hidradenitis Suppurativa Further Strengthen Competitive Profile of Izokibep
• Phase 3 trial of izokibep in patients with hidradenitis suppurativa met primary endpoint of HiSCR75 at week 12, as well as the key secondary endpoints of HiSCR90 and HiSCR100.• Data from two-thirds of trial participants who have completed week 16 demonstrate deepening of responses over time.• No new safety signals were identified, and the favorable safety profile demonstrated in previous trials was confirmed.
Stockholm, Sweden, August 13, 2024. Affibody’s partner ACELYRIN, INC. today announced that the Phase 3 trial of the Affibody® molecule izokibep in patients with hidradenitis